BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Remix Therapeutics said it received positive preliminary results for the ongoing Phase 1 of its lead drug, REM-422, in ...

Biogen will pay a Chicago biotech $70 million upfront, plus up to $990 million in milestone payments, for an early-stage ...

A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data ...

Biogen specializes in therapies for complex neurological and neurodegenerative conditions. With a diversified product suite ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

Swiss investment company BB Biotech reported an outstanding third quarter in 2025. Here’s why.

The state’s difficulties in the last year are indicative of wider industry problems during a time of market trepidation, as ...

MRANTI launches new Biotechnology Sandbox to help local researchers fast-track solutions from lab to market. Here are the ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...